Shopping Cart

Your shopping cart is currently empty

GLPG2534

Name: GLPG2534
Brand: TargetMol
SKU: T75113
Price: 113 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Catalog No. T75113Cas No. 2095615-97-5

Alias GLPG-2534

GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.

GLPG2534

🥰Excellent

Purity: 99.61%

Catalog No. T75113Alias GLPG-2534Cas No. 2095615-97-5

GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$113	In Stock	In Stock
5 mg	$278	In Stock	In Stock
10 mg	$455	In Stock	In Stock
25 mg	$886	In Stock	In Stock
50 mg	$1,450	In Stock	In Stock
100 mg	$2,320	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

Questions

Batch Information

Select Batch

Purity:99.61%

Appearance:Solid

Color:Yellow

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.
Targets&IC50	IL-1β:55 nM, IRAK1:179 nM, mIRAK4:3.5 nM, IRAK4 (human):6.4 nM
In vitro	GLPG2534 inhibits IL-6 release driven by IL-1β with an IC50 of 55 nM[1]. It also inhibits TNF-α-driven IL-6 release, with an IC50 of 6.6 μM[1]. When applied at concentrations ranging from 0.1 to 10 μM for 16 hours, GLPG2534 inhibits the expression of S100A7, DEFB4A, CXCL8, and TNF in ciliated epithelial cells stimulated with ciliogenesis-promoting factors[1].
In vivo	GLPG2534, administered orally at doses ranging from 0.3 to 10 mg/kg, inhibits CL097-driven TNF-α release in mouse blood[1]. Furthermore, oral administration of GLPG2534 at doses of 10 and 30 mg/kg, twice daily, alleviates inflammation in a psoriasis-like mouse model[1]. Additionally, GLPG2534, at doses of 3-30 mg/kg, orally administered twice daily for 5 days, mitigates the development of IL-33 and MC903-induced atopic dermatitis-like skin inflammation in mice[1].
Synonyms	GLPG-2534

Chemical Properties

Molecular Weight	424.45
Formula	C₂₁H₂₄N₆O₄
Cas No.	2095615-97-5
Smiles	N#CC1=CN=C(C=C1)N2C=NC=3C=C(OCCOCCO)C(=NC32)NC4CCOCC4

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 80 mg/mL (188.48 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.3560 mL	11.7800 mL	23.5599 mL	117.7995 mL
5 mM	0.4712 mL	2.3560 mL	4.7120 mL	23.5599 mL
10 mM	0.2356 mL	1.1780 mL	2.3560 mL	11.7800 mL
20 mM	0.1178 mL	0.5890 mL	1.1780 mL	5.8900 mL
50 mM	0.0471 mL	0.2356 mL	0.4712 mL	2.3560 mL
100 mM	0.0236 mL	0.1178 mL	0.2356 mL	1.1780 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc